Meeting
2018 Gastrointestinal Cancers Symposium
A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
Authors
Andrew X. Zhu
Massachusetts General Hospital/ Harvard Medical School, Boston, MA
Andrew X. Zhu , Peter R. Galle , Masatoshi Kudo , Richard S. Finn , Shukui Qin , Yihuan Xu , Paolo Abada , Josep Llovet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02435433
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS538)
DOI
10.1200/JCO.2018.36.4_suppl.TPS538
Abstract #
TPS538
Poster Bd #
Q14
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2).
First Author: Maria Reig
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2016 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2015 Gastrointestinal Cancers Symposium
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study.
First Author: Andrew X. Zhu